|Bid||0.0860 x 250000|
|Ask||0.0870 x 1097400|
|Day's range||0.0870 - 0.0890|
|52-week range||0.0810 - 0.5350|
|Beta (5Y monthly)||1.08|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Exopharm Limited (ASX:EX1) has signed a Master Collaborative Services Agreement (MSA) with the Astellas Institute for Regenerative Medicine (AIRM).
Exopharm Limited (ASX:EX1) has been granted US patent US 11202805 for its LEAP™ exosome purification technology. This patent positions Exopharm as a global leader in meeting the challenge of large-scale, commercial production of exosomes needed to enable leading-edge exosome medicines.